Considerations for design, manufacture, and delivery for effective and safe T-cell engager therapies
- 27 September 2022
- journal article
- review article
- Published by Elsevier in Current Opinion in Biotechnology
- Vol. 78, 102799
Abstract
No abstract availableKeywords
Funding Information
- Amgen
This publication has 48 references indexed in Scilit:
- Challenges and opportunities in the purification of recombinant tagged proteinsBiotechnology Advances, 2014
- Blinatumomab: A historical perspectivePharmacology & Therapeutics, 2012
- Targeted Therapy With the T-Cell–Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free SurvivalJournal of Clinical Oncology, 2011
- Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomabExperimental Cell Research, 2011
- Enhancing Antibody Fc Heterodimer Formation through Electrostatic Steering EffectsJournal of Biological Chemistry, 2010
- MT110: A novel bispecific single-chain antibody construct with high efficacy in eradicating established tumorsMolecular Immunology, 2006
- Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cellsMolecular Immunology, 2006
- T-cell activation and B-cell depletion in chimpanzees treated with a bispecific anti-CD19/anti-CD3 single-chain antibody constructCancer Immunology, Immunotherapy, 2005
- Extremely potent, rapid and costimulation‐independent cytotoxic T‐cell response against lymphoma cells catalyzed by a single‐chain bispecific antibodyInternational Journal of Cancer, 2002
- Stability engineering of antibody single-chain Fv fragmentsJournal of Molecular Biology, 2001